A practical reference on GHRH analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-09 and is reviewed periodically as new material appears.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
=== Management === Overdose is usually treated symptomatically, especially in the case of serotonin syndrome, which requires treatment with cyproheptadine and temperature control based on the progression of the serotonin toxicity. Patients are often monitored for vitals and airways cleared to ensure that they are receiving adequate levels of oxygen. Another option is to use activated carbon in the GI tract in order to absorb excess neurotransmitter.
=== Ulcerative colitis === Vedolizumab has been investigated in several studies in adult patients. Patients with moderate to severe active disease in whom conventional therapy or TNF-alpha antagonists were ineffective or could not be tolerated received either vedolizumab or placebo. The main measure of effectiveness was the proportion of patients whose symptoms improved after six weeks of treatment. Vedolizumab was shown to be more effective than placebo: 47% (106 out of 225) of patients who received vedolizumab showed an improvement in symptoms, compared with 26% (38 out of 149) of patients who received placebo. The study also showed that vedolizumab maintained the effect up to 52 weeks more effectively than placebo. Moreover, vedolizumab treatment was shown to achieve higher percentage of clinical remissions (31.3% vs. 22.5%) in patients with ulcerative colitis in comparison to adalimumab treatment.
FAs can be further processed in the endoplasmic reticulum, where they are joined to a glycerol backbone in groups of three to form triacylglycerol (TAG), or in pairs (with the addition of a polar head group on the C1 of glycerol) to form a phospholipid. Fatty acids are classified according to the number of carbon double bonds present about the aliphatic hydrocarbon chain. Saturated fatty acids have no double bonds. Monounsaturated fatty acids have one double bond, while polyunsaturated fatty acids have two or more double bonds present about the hydrocarbon chain. Saturated fatty acids are a primary constituent of glycerolipids, as well as the phospholipids and sphingolipids found in cellular membranes. Common saturated fatty acids include palmitic acid, butyric acid, and stearic acid, all of which contribute to LDL cholesterol levels and increase the risk of obesity, heart disease, and stroke. Monounsaturated fatty acids are also primary constituent of glycerolipids and cellular membrane structures. Monounsaturated fatty acids include oleic acid, palmitoleic acid, and vaccenic acid, which help lower LDL cholesterol and reduce the risk of heart disease and stroke. Polyunsaturated fatty acids are found in the phospholipids of cell membranes, and are also known to act as precursors for a variety of lipid signaling molecules. Common polyunsaturated fatty acids include the essential omega-3 and omega-6 fatty acids, which are crucial for brain, heart, and immune health.
=== Proposed re-engined versions === In the 1980s, there were moves to fit the Il-86 with RB211-22 engines. Designated Il-86V (second use of this designation), this would have had a range of over 9,000 km (4,860 nmi) and/or increased payload. Another 450-seater Il-86V powered by RB211-524G engines was also projected. Amid the disintegration of the Soviet economy, these versions did not progress. In 1991, there were moves to fit the Il-86 with Franco-American CFM56-5C2 engines. Finances precluded progress. In 1995, International Aero Engines offered the V2500 engine to five Il-86 operators with proposals to re-engine 25 aircraft. The offer was not taken up.
== Prevention == Many types of dwarfism are currently impossible to prevent because they are genetically caused. Genetic conditions that cause dwarfism may be identified with genetic testing, by screening for the specific variations that result in the condition. However, due to the number of causes of dwarfism, it may be impossible to determine definitively if a child will be born with dwarfism. Dwarfism resulting from malnutrition or a hormonal abnormality may be treated with an appropriate diet or hormonal therapy. Growth hormone deficiency may be remedied via injections of human growth hormone during childhood.
Sources: en.wikipedia.org
=== In humans === Although generally considered safe to use, it is neurotoxic to humans in high doses. Pyrethroids like deltamethrin can also be an allergen that provokes asthma in some people. Deltamethrin temporarily attacks the nervous system of any animal with which it comes into contact. Skin contact can lead to tingling or reddening of the skin local to the application. If taken in through the eyes or mouth, the most common symptom is facial paraesthesia, which can feel like many different abnormal sensations, including burning, partial numbness, "pins and needles", skin crawling, etc. There is one case report describing chronic intoxication from pyrethroid insecticides leading to a syndrome clinically similar to motor neuron disease. There are no antidotes, and treatment must be symptomatic, as approved by a physician. Over time, deltamethrin is metabolized, with a rapid loss of toxicity, and passed from the body. A poison control center should be contacted in the event of an accidental poisoning. Deltamethrin is able to pass from a woman's skin through her blood and into her breast milk, although breastfeeding remains safe under prevailing conditions. In South Africa, residues of deltamethrin were found in breast milk, together with DDT, in an area that used DDT treatment for malaria control, as well as pyrethroids in small-scale agriculture. A 2015 study conducted in Brittany, France, found a negative correlation between deltamethrin exposure (measured through the presence of a metabolite in urine) and cognitive scores in infants.
While it was known that plants expressing virus-specific proteins showed enhanced tolerance or resistance to viral infection, it was not expected that plants carrying only short, non-coding regions of viral RNA sequences would show similar levels of protection. Researchers believed that viral RNA produced by transgenes could also inhibit viral replication. The reverse experiment, in which short sequences of plant genes were introduced into viruses, showed that the targeted gene was suppressed in an infected plant. This phenomenon was labeled "virus-induced gene silencing" (VIGS), and the set of such phenomena were collectively called post transcriptional gene silencing. After these initial observations in plants, laboratories searched for this phenomenon in other organisms. The first instance of RNA silencing in animals was documented in 1996, when Guo and Kemphues observed that, by introducing sense and antisense RNA to par-1 mRNA in Caenorhabditis elegans caused degradation of the par-1 message. It was thought that this degradation was triggered by single-stranded RNA (ssRNA), but two years later, in 1998, Fire and Mello discovered that this ability to silence the par-1 gene expression was actually triggered by double-stranded RNA (dsRNA). Craig C. Mello and Andrew Fire's 1998 Nature paper reported a potent gene silencing effect after injecting double stranded RNA into C. elegans.
== Partitioning and transmutation strategy == Many efforts are being devoted to develop an advanced reprocessing approach with the aim to further reduce the radiotoxicity inventory of the spent nuclear fuel by removing all minor actinides (Neptunium, Americium and Curium) and the long-lived fission products (LLFP) from the high active raffinate downstream of the PUREX process. Before the conditioning process, the long-lived radionuclides undergo a transmutation into short-lived or stable nuclides by nuclear reactions. This coupled approach is known as Partitioning and Transmutation strategy (P&T), which inclusion in an advanced closed fuel cycle could lead to strongly reduce long-term radiotoxicity, volume and decay heat of the final waste thus simplifying a performance assessment of a future nuclear waste repository and enhancing proliferation resistance criteria. Two potential process options for the partitioning of spent nuclear fuel are being developed: hydrometallurgical and pyrometallurgical processes. The hydrometallurgical partitioning, also known as solvent extraction process, was born and developed in Europe thereby becoming the reference technology for future SNF reprocessing at industrial level, whereas the pyrometallurgical option started in the United States and Russia as an alternative to the aqueous processes.
In September 2022, the ministry reported: "Repair work on the Cinesphere, pods, and bridges is proceeding on schedule this fall. Site servicing, including sewage, water, electrical, and gas, is expected to begin in the spring of 2023." Therme Canada's local partners are the Toronto International Film Festival (TIFF), Mississaugas of the Credit First Nation, and Black North Initiative. TIFF later 'paused' their relationship with Therme ahead of their 2023 festival. Other partners include AECON Group Inc., Diamond Schmitt, and Studio TLA. Strategy Corp is serving Therme Canada with strategy and communications. Swim Drink Fish Canada was a partner, but exited the partnership in the belief that the government's portion of the plan is "simply too opaque and controversial for us to support". Therme's plans have received strong public backlash, with the group Ontario Place for All leading the campaign against the development. Plans to develop the public space and existing beach by a for-profit private developer became a prominent 2023 election issue in Toronto. The mayoral campaign saw mayor Olivia Chow come out in opposition to the project. Later in 2023, she dropped her opposition to the project when the City and Government of Ontario reached an agreement for the transfer of the two Toronto freeways (Don Valley and Gardiner) to the province, saving the city an estimated $1.2 billion. The community group has continued its opposition, attempting to stop or slow down the project in the courts.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.